MONTREAL, December 12, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a functional cure for patients with chronic HBV infection and HBV / HDV co-infection announced today the publication of its in vitro study of the activity of NAPs in various tissue culture models of HDV infection in the Journal of Virology (http://jvi.asm.org/content/early/2017/11/30/JVI.01416-17.long).
This in vitro study was conducted in collaboration with Dr. Camille Sureau at the Institut National de la Transfusion Sanguine in Paris, France and is the sister study to the previously published in vitro evaluation of NAPs in HBV infection (http://replicor.com/replicor-announces-publication-studies-antiviral-activity-naps-recognized-vitro-models-hbv-infection/).
Similar to the findings reported in the HBV study, early generation NAPs like REP 2055 had a mild ability to block HDV infection while the current clinical lead NAP REP 2139, previously shown to have a direct and potent antiviral activity against HDV (http://replicor.com/replicor-announces-publication-rep-301-study-hbv-hdv-co-infection-lancet-gastroenterology-hepatology/), displayed no entry inhibitory activity against HDV and negligible interaction with HDV or HBV virions.
Dr. Andrew Vaillant, CSO of Replicor commented, “As with our previous study in HBV, the arrested trafficking of NAPs in tissue culture, which functions normally in hepatocytes in vivo and drives potent antiviral effects in patients, made the observation of post-entry antiviral effects difficult in this tissue culture study. However, these data again demonstrate that the antiviral effects of REP 2139 against HDV infection in patients are achieved independently from any effect on viral entry and continue to drive our focus on defining the post-entry mechanisms of NAPs in HDV infection using a variety of techniques designed to overcome the arrested trafficking of NAPs in tissue culture”.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of a functional cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.